The horseshoe crab has endured for over 450 million years. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall.
During the last several decades Boston has become a biotech Mecca, with its Kendall Square attracting more than 120 biotech companies, both large and small. It is called the most innovative square mile on the planet. This June BIO will bring over 15,000 biotech leaders to Boston for its 2023 BIO International Convention. Speakers including award-winning journalist and health advocate, Katie Couric, will talk about how they will “Stand up for Science”—the Convention’s theme. MassBIO CEO, Kendalle Burlin O’Connell joins host, Rachel King in a wide-ranging discussion about how Boston became the largest biotech hub in the world.
Guests include: Host-Rachel King, CEO, Biotechnology Innovation Organization (BIO); Kendalle Burlin O’Connell, President & CEO, MassBio
Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation.
Guests include: Dr. Robert Califf, Commissioner, U.S. Food & Drug Administration; Dr. Reed Tuckson, Cofounder, Coalition for Trust in Health & Science and Black Coalition Against COVID; Jules Bernstein, Senior Public Information Officer, University of California at Riverside
The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. Lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind.
Guests include: Alain Berinstan, Chief Strategy Officer, Space Tango; Jana Stoudemire, Director of In-space Manufacturing, Axiom Space; Nicole Wagner, President & CEO, LambdaVision
CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier.
Guests include: Leah Sabin, Executive Director, Regeneron Genetics Medicines, Regeneron; David Gutstein, Program Head for Bleeding and Clotting Disorders, Regeneron; Julie Bruno, SVP of Programs and Portfolio, CRISPR Therapeutics; Benjamin Oakes, Co-founder and CEO, Scribe Therapeutics
When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval.
Guests include: John Crowley, Executive Chairman, Amicus Therapeutics; Emil D. Kakkis, CEO and President, Ultragenyx; Cartier Esham, Chief Scientific Officer, BIO; Duane Schulthess, CEO, Vital Transformation
The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments.
Guests include: Bertrand Adanve, Founder and CEO of Genetic Leap; Sree Kant, Founder and CEO, BAKX Therapeutics; Nick Nystrom, Chief Technology Officer at Peptilogics; Maria Cho, CEO of Triplebar
Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies.
Guests include: Cindy Steinberg, Director of Policy & Advocacy, U.S. Pain Foundation; David Thomas, Senior Vice President of Research & Analysis, BIO; Paul Negulescu, Senior Vice President & Disease Area Executive for the Pain Program, Vertex; Hernan Bazan, CEO and Co-Founder, South Rampart Pharma
Talking about women’s health has been a taboo subject for some time, contributing to a lack of innovation in the sector. Still today, many are uncomfortable discussing the topic. Consequently, only 2% of medical products in the pipeline are for women’s health and only 2% of all venture capital dollars go into developing these products. In this episode, we talk with two women in biotech who are trying to change that narrative and infuse more investment in innovations that meet the needs of half the population.
Guests include: Sabrina Martucci Johnson, CEO, Daré Bioscience; Elizabeth Bailey, Managing Director RH Capital
Plastic is polluting our waterways and oceans, but biotechnology may deliver solutions. Plant-based bioplastics that can break down in months are one solution. Another is mighty microbes bioengineered to speed up consumption of plastic. This episode spotlights scientists, companies and even a filmmaker and artist who are working in different ways to tackle the growing problem of plastic waste.
Guests include: Scott Tuten, Chief Marketing and Sustainability Officer, Danimer Scientific, Andrew Held, Vice President of Engineering & Business, Virent, Dr. Tae Seok Moon, Associate Professor of Energy, Environmental & Chemical Engineering, Washington University in St. Louis, Founder and head of the Scientific Advisory Board, Moonshot Bio, Ben Lear, Independent Film Producer/Director
Not that long ago psychedelics were considered dangerous, and only enjoyed recreationally by a fringe element of society. Today, researchers are looking at drugs like psilocybin to develop treatments for depression, PTSD, addiction, and anxiety. This episode features guests steeped in the world of psychedelics who are finding new ways to treat mental health.
Guests include: Susan Ruediger, Founder and Chief Mission Officer, CMT Research Foundation and Nasha Fitter, CEO, FOXG1 Research Foundation
Patient Advocates do more than raise money—they are active participants in the drug development process. While the ALS Ice Bucket Challenge garnered global attention, lesser-known patient advocates also flex their expertise to drive new treatments and cures. In this episode, we talk with two moms, one who is a patient herself, about their work as partners in research and development, helping bring treatments for two rare diseases to the market.
Guests include: Susan Ruediger, Founder and Chief Mission Officer, CMT Research Foundation and Nasha Fitter, CEO, FOXG1 Research Foundation
Monkeypox hit our shores in May of this year. How did our public health agencies and infrastructure perform? What went right, what went wrong, and what needs to improve? We talked with three experts in public health and biodefense about the threats on their radar screens and how the U.S. can better prepare for the next inevitable outbreak or pandemic.
Guests include: Dr. Asha George, Bipartisan Commission on Biodefense; Dr. Lynn Goldman, Milken Institute School of Public Health at the George Washington University; Dr. John Redd, Medical Countermeasures Coalition
You might be surprised to learn that data storage currently requires huge amounts of land and energy, and we're running out of both. In this episode, we speak with a group of researchers who are revolutionizing the way we store massive amounts of data. Their solution: DNA.
Guests include: Emily Leproust, Twist Bioscience; Kyle Tomek, DNALi Data Technologies; Jeff Nivala, University of Washington
Current market trends have put investors in a “flight-to-safety” mentality, especially when it comes to biotech companies. What does this mean for getting biotech innovations to the marketplace? This episode explores the daunting challenge of raising capital in a bear market.
A convoluted, confusing, and opaque system for pricing drugs has evolved that distorts the market and often limits patient access to the drugs they need to survive. In this episode, three experts explain how the system works—or doesn’t’—and the consequences of a dysfunctional pricing system.
Speakers: Anna Hyde - Arthritis Foundation, Dan Durham - BIO, Dr. Vinay Rathi - Massachusetts Eye and Ear and Mass General Brigham
Alzheimer’s disease is a heartbreaking diagnosis and tragically there is no cure. But every day, researchers, scientists and the medical community are working to change that. In this episode, we speak with three guests who are fighting to bend the trajectory of Alzheimer’s disease and, in doing so, offering hope for the millions suffering from this devastating illness.
Last December, a United Airlines flight from Chicago to Washington DC was the first ever passenger flight powered with 100% sustainable aviation fuel. The achievement demonstrated the potential for the aviation sector to reduce its carbon footprint. Our guests in this episode each played a key role in helping the airline reach this exciting milestone.
Speakers: Laura Riley, Chief Sustainability Officer at United; Dave Kettner, President & CEO of Virent, Inc.
2021 was the unofficial year of mRNA—and deservedly so. But the science behind the technology is not always easy to understand. In this episode, we will dive into the miracle technology that saved countless lives and why the healthcare ecosystem will always need multiple options.
More than two-thirds of the Earth’s surface is water, and yet water that is safe enough for human consumption remains a finite resource. In this episode, we speak to experts about the biggest threats to water—contamination, overuse, and plastic. We also learn how innovative new tools can ensure there is enough water to hydrate us, our plants, and our animals.
Speakers: Ameen Razavi, Microvi Biotech; Dr. Joel Cuello, University of Arizona; Scott Tuten, Danimer Scientific